UConn Health

Running trials

• Recruiting

  A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression

  NCT07716098· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  Impact of Educational Videos on Pre-operative Anxiety

  NCT07740759· UConn Health· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Novel Digital Tool Clinicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors

  NCT07238556· University of Connecticut· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT07213973· Phase 2· Incyte Corporation· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Daily Amino Acid Supplementation for People With Parkinson's Disease

  NCT07115563· Cristina Colon-Semenza· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

  NCT06924970· Phase 2· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  Novel Approaches to the Treatment of Hypothyroidism

  NCT06731764· Phase 2/3· UConn Health· Source

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Biohaven Therapeutics Ltd.· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

  NCT06463587· Phase 3· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Biohaven Therapeutics Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05571059· Phase 2· Cumberland Pharmaceuticals· Source

• Recruiting

  Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  NCT05980949· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Recruiting

  Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

  NCT05850689· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Enrolling by invitation

  A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05735483· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT05559359· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait

  NCT07083531· UConn Health· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

• Active, not recruiting

  LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321420· Phase 2· PureTech· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Predictors of Cognitive Outcomes in Geriatric Depression

  NCT05273996· Phase 4· David Steffens· Source

• Active, not recruiting

  CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

  NCT04495153· Phase 2· Candel Therapeutics, Inc.· Source

• Active, not recruiting

  Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

  NCT04498117· Phase 3· CanariaBio Inc.· Source

• Active, not recruiting

  An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

  NCT04053803· Phase 2· Imara, Inc.· Source

• Recruiting

  Pulmonary Hypertension Association Registry

  NCT04071327· Pulmonary Hypertension Association, Inc.· Source

• Active, not recruiting

  Sickle Cell Hemoglobinopathies and Bone Health

  NCT02306993· UConn Health· Source

• Recruiting

  Study of Circulating Monocytes in Patients With Ischemic Vascular Disease

  NCT04321512· UConn Health· Source

• Active, not recruiting

  Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

  NCT01844986· Phase 3· AstraZeneca· Source

• Recruiting

  Circulating Markers for Ischemic Heart Disease

  NCT00762333· UConn Health· Source

• Recruiting

  Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure

  NCT00762008· UConn Health· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression3 recruiting
• Alzheimer disease2 recruiting
• Coronary artery disease2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Multiple myeloma2 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Endometriosis1 recruiting
• Epilepsy1 recruiting
• Hidradenitis suppurativa1 recruiting
• Hypothyroidism1 recruiting
• Insomnia1 recruiting
• Lung cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Myasthenia gravis1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Schizophrenia1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  A Targeted Amino Acid Supplement for People With Parkinson's Disease

  NCT06954662· Early phase 1· UConn Health· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  NCT06667908· Phase 2· Johnson & Johnson Enterprise Innovation Inc.· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Recruiting

  IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

  NCT06112314· Phase 3· Immunocore Ltd· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

  NCT06280391· Phase 2· Sanofi· Source

• Completed

  Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

  NCT05861453· Phase 2· Afimmune· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

  NCT06181435· Phase 3· Sanofi· Source

• Completed

  A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

  NCT05841030· Janssen Research & Development, LLC· Source

• Completed

  Brain-Training Treatment for Long COVID in Older Adults

  NCT05705193· UConn Health· Source

• Completed

  A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

  NCT05372419· Phase 3· Eli Lilly and Company· Source

• Completed

  Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

  NCT05616221· Phase 2· Armata Pharmaceuticals, Inc.· Source

• Completed

  A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

  NCT05369403· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Terminated

  POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)

  NCT05299606· Ethicon, Inc.· Source

• Completed

  Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

  NCT05272150· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05455684· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  Oxbryta® Product Registry An Observational Study Designed to Evaluate the Effect of Oxbryta in Individuals With SCD

  NCT04930445· Pfizer· Source

• Completed

  Walnuts and Colon Health (The WellNut Trial)

  NCT05195970· UConn Health· Source

• Completed

  A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  NCT04599855· Phase 4· Janssen Research & Development, LLC· Source

• Completed

  LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

  NCT04479241· Phase 2· Istari Oncology, Inc.· Source

• Completed

  A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

  NCT04533529· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung

  NCT04182815· Auris Health, Inc.· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

  NCT03938454· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  A Reinforcement Intervention for Increasing HIV Testing Among At-Risk Women

  NCT03768986· UConn Health· Source

• Completed

  A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )

  NCT03047395· Phase 3· AbbVie· Source

• Completed

  Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)

  NCT02553642· Phase 2· Memorial Sloan Kettering Cancer Center· Source

• Completed

  Clinical Registry of Long-Term Dental Outcomes in Head and Neck Cancer Patients

  NCT05325970· Wake Forest University Health Sciences· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Sickle cell disease25 works · 8 trials
• Bronchiectasis19 works · 3 trials
• Endometriosis13 works · 1 trial
• Hidradenitis suppurativa10 works · 1 trial
• Fibromyalgia6 works · 0 trials
• Barrett's oesophagus3 works · 0 trials